|[February 19, 2014]
Ezose Sciences Receives Grant from Michael J. Fox Foundation to Use GlycanMap® Technology in Parkinson's Research
PINE BROOK, N.J. --(Business Wire)--
Ezose Sciences Inc. today announced that it has received a grant from
The Michael J. Fox Foundation for Parkinson's Research to apply Ezose's
GlycanMap® technology to investigating the role of the sugars
known as glycans in Parkinson's disease.
Ezose's GlycanMap® technology enables automated analysis of
glycans, which attach to proteins in the body and affect their
biochemical function. The speed, scope, and quantitative power of this
technology hold the potential for discovering novel glycan changes
associated with altered protein function during the onset and
progression of wide-ranging diseases, including Parkinson's disease and
other neurological disorders. Glycans could serve as novel biomarkers
for guiding clinical management and drug development and provide insight
into disease mechanism and novel drug targets.
The research funded by the foundation will be performed in Ezose's
laboratories, where the GlycanMap® assay will be used to compare
glycan profiles in brain-stem tissue from rat models of Parkinson's
disease and control rats over time and with respect to development of
"The Michael J. Fox Foundation has brought a tireless sense of urgency
to advancing research into Parkinson's disease," said Ryuichi Kiyama,
Ph.D., Chairman and Chief Executive Officer of Ezose. "We look forward
to bringing that spirit as well as our technical capabilities to this
novel research project."
Mark Frasier, Ph.D., Vice President of Research Programs at The Michael
J. Fox Foundation, commented: "Two important steps toward the
development of a disease-modifying therapy for Parkinson's are greater
understanding of the underlying pathology of the disease and validation
of a reliable biomarker. Ezose's glycan analysis offers a new approach
to serve those goals and bring us closer to a Parkinson's cure."
About Parkinson's Disease
Parkinson's disease is a chronic, degenerative, neurological disorder
that ffects at least one million people in the United States alone.
Motor symptoms include physical rigidity, slowness of movement, and
tremors in resting limbs. Non-motor symptoms include cognitive
impairment, mood disorders, and loss of the sense of smell. The range
and severity of symptoms vary widely among individuals.
Glycomics is the study of glycans, the sugar chains that during the
biochemical process known as glycosylation become attached to many
proteins expressed by human cells. The particular glycans involved may
crucially determine the function of the resulting glycoprotein and its
role in health and disease.
Glycomics is a natural complement to genomics and proteomics, but it has
traditionally been hindered by the lack of practical high-throughput and
quantitative technologies. Ezose's proprietary GlycanMap®
platform addresses this need by combining, in an automated 96-well
format, high-throughput glycan enrichment with specialized MALDI-TOF
mass spectrometry and custom bioinformatics to both structurally
identify and quantitate glycans present in complex biological samples.
Such glycans can serve as novel biomarkers to aid in the development of
drugs, vaccines, and diagnostic tests, including companion diagnostics.
In addition, glycomics holds potential for uncovering new therapeutic
targets and mechanisms and for guiding the development and manufacture
of glycosylated biologics and biosimilars.
Ezose (pronounced a-zose) Sciences Inc., based in Pine Brook, NJ, is
dedicated to advancing glycomics to improve scientific understanding and
healthcare. Ezose's proprietary GlycanMap® technology platform
brings a new dimension to biomarker discovery by enabling glycomics
research on a scale comparable to that of genomics and proteomics. Ezose
offers glycomics capabilities ranging from glycan analytics and
biomarker discovery to diagnostic development and commercialization. The
company tailors these capabilities to the needs of corporate partners
under collaborative R&D and analytical-services agreements.
Established in 2009 as a US company, Ezose is an affiliate of the
Diagnostics Division of Shionogi & Co., Ltd., Osaka, Japan.
For more information, visit www.ezose.com.
Forward Looking Statements
This announcement contains forward-looking statements. These
statements are based on expectations in light of the information
currently available, assumptions that are subject to risks and
uncertainties which could cause actual results to differ materially from
these statements. Risks and uncertainties include general domestic and
international economic conditions such as general industry and market
conditions, and changes of interest rate and currency exchange rate.
These risks and uncertainties particularly apply with respect to
product-related forward-looking statements. Product risks and
uncertainties include, but are not limited to, completion and
discontinuation of clinical trials; obtaining regulatory approvals;
claims and concerns about product safety and efficacy; technological
advances; adverse outcome of important litigation; domestic and foreign
healthcare reforms and changes of laws and regulations. Also for
existing products, there are manufacturing and marketing risks, which
include, but are not limited to, inability to build production capacity
to meet demand, unavailability of raw materials and entry of competitive
products. The company disclaims any intention or obligation to update or
revise any forward looking statements whether as a result of new
information, future events or otherwise.
[ Back To TMCnet.com's Homepage ]